SG11201811433TA - Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method - Google Patents

Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method

Info

Publication number
SG11201811433TA
SG11201811433TA SG11201811433TA SG11201811433TA SG11201811433TA SG 11201811433T A SG11201811433T A SG 11201811433TA SG 11201811433T A SG11201811433T A SG 11201811433TA SG 11201811433T A SG11201811433T A SG 11201811433TA SG 11201811433T A SG11201811433T A SG 11201811433TA
Authority
SG
Singapore
Prior art keywords
marker
ovarian cancer
cancer prognosis
diagnosis
prediction
Prior art date
Application number
SG11201811433TA
Inventor
Takahiro Ochiya
Akira Yokoi
Tomoyasu Kato
Original Assignee
Nat Cancer Ct
Biomimetics Sympathies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct, Biomimetics Sympathies Inc filed Critical Nat Cancer Ct
Publication of SG11201811433TA publication Critical patent/SG11201811433TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

MMP1 GENE TRANSCRIPT FOR USE AS MARKER FOR DIAGNOSIS OF OVARIAN CANCER PROGNOSIS, AND TEST METHOD 5 [Problem] To provide: a marker and a kit both for use in the prediction of ovarian cancer prognosis; and a prognosis prediction method. [Solution] A marker and a kit, both for use in the prediction of ovarian cancer prognosis, each of said marker and kit containing a transcript of matrix metalloprotease (MMP) 1gene; and a method for 10 predicting ovarian cancer prognosis using the marker or the kit, in which the expression level of matrix metalloprotease (MMP) 1 gene in a biological sample collected from a subject is by detecting an ovarian cancer prognosis prediction marker comprising a transcript of matrix metalloprotease (MMP) 1gene and then obtaining a detection value of the ovarian cancer prognosis prediction marker. 15 [Figure 1]
SG11201811433TA 2016-06-20 2017-06-20 Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method SG11201811433TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016121392A JP6143920B1 (en) 2016-06-20 2016-06-20 MMP1 gene transcripts and test methods as prognostic markers for ovarian cancer
PCT/JP2017/022680 WO2017221927A1 (en) 2016-06-20 2017-06-20 Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method

Publications (1)

Publication Number Publication Date
SG11201811433TA true SG11201811433TA (en) 2019-01-30

Family

ID=59012109

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811433TA SG11201811433TA (en) 2016-06-20 2017-06-20 Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method

Country Status (8)

Country Link
US (1) US20190316205A1 (en)
EP (1) EP3473729A4 (en)
JP (1) JP6143920B1 (en)
CN (1) CN110023510A (en)
AU (1) AU2017282420A1 (en)
CA (1) CA3067527A1 (en)
SG (1) SG11201811433TA (en)
WO (1) WO2017221927A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114752673B (en) * 2022-04-30 2023-07-28 重庆大学附属肿瘤医院 Application of reagent for detecting ISYNA1 expression level in preparation of ovarian cancer dryness identification reagent
WO2024009946A1 (en) * 2022-07-08 2024-01-11 国立大学法人東海国立大学機構 Method for testing effectiveness of parp inhibitor against ovarian cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048734A2 (en) * 2001-12-03 2003-06-12 Oncomedx, Inc. Detection of matrix metalloproteinase rna in plasma and serum
AU2012220896B2 (en) * 2011-02-24 2016-11-24 Aspira Women’s Health Inc. Biomarker panels, diagnostic methods and test kits for ovarian cancer
US20150072947A1 (en) 2011-08-30 2015-03-12 National Defense Medical Center Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
AU2013331154B2 (en) * 2012-10-17 2018-02-01 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer

Also Published As

Publication number Publication date
CA3067527A1 (en) 2017-12-28
CN110023510A (en) 2019-07-16
EP3473729A4 (en) 2020-02-26
JP6143920B1 (en) 2017-06-07
US20190316205A1 (en) 2019-10-17
AU2017282420A1 (en) 2019-02-07
EP3473729A1 (en) 2019-04-24
JP2017225352A (en) 2017-12-28
WO2017221927A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
GB2568608A (en) Personalized genetic testing
MX2013001042A (en) Pancreatic cancer biomarkers and uses thereof.
MX2014003153A (en) Cardiovascular risk event prediction and uses thereof.
MA39951A (en) Detection of dna that originates from a specific cell-type and related methods
EP3988668A3 (en) Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
MY170164A (en) Aptamer-based multiplexed assays
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
WO2014065889A3 (en) Multiplexed method for diagnosing classical hodgkin lymphoma
WO2012096545A3 (en) Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
EA030186B9 (en) Method for performing quantitation assays
IN2014CN01787A (en)
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
BR112022011676A2 (en) KIT TO DETECT AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES, METHOD TO DETECT AND/OR QUANTIFY IT AND CARTRIDGE TO PERFORM SUCH METHOD
WO2018097614A3 (en) Method for predicting effectiveness of chemotherapy in breast cancer patients
MX2015013415A (en) Method and system for analyzing biological specimens by spectral imaging.
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
WO2015091575A3 (en) Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer
WO2012050365A3 (en) Biomarker for diagnosing glioblastoma or predicting prognosis of glioblastoma patients, and use thereof
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
MX369610B (en) Methods, devices, and systems for sample analysis.